Cargando…

Randomized trial of daily high-dose vitamin D(3) in patients with RRMS receiving subcutaneous interferon β-1a

OBJECTIVE: In the phase II, randomized, double-blind, placebo-controlled Supplementation of Vigantol Oil versus Placebo Add-on in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Receiving Rebif Treatment (SOLAR) study (NCT01285401), we assessed the efficacy and safety of add-on vitamin D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hupperts, Raymond, Smolders, Joost, Vieth, Reinhold, Holmøy, Trygve, Marhardt, Kurt, Schluep, Myriam, Killestein, Joep, Barkhof, Frederik, Beelke, Manolo, Grimaldi, Luigi M.E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946471/ https://www.ncbi.nlm.nih.gov/pubmed/31594857 http://dx.doi.org/10.1212/WNL.0000000000008445

Ejemplares similares

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

An Update on Vitamin D and Disease Activity in Multiple Sclerosis
por: Smolders, Joost, et al.
Publicado: (2019)

Distinct binding properties of TIAR RRMs and linker region
por: Kim, Henry S., et al.
Publicado: (2013)

Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database
por: Allignol, Arthur, et al.
Publicado: (2021)

Oral available agents in the treatment of RRMS
por: Aupérin, Thierry
Publicado: (2013)

Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only
por: Kalra, S, et al.
Publicado: (2020)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: Lesage, E., et al.
Publicado: (2010)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
por: Vališ, Martin, et al.
Publicado: (2020)

Cortical Pathology in RRMS: Taking a Cue from Four Sisters
por: Calabrese, Massimiliano, et al.
Publicado: (2012)

Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
por: Davis, Mat D., et al.
Publicado: (2017)

Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization
por: De Stefano, Nicola, et al.
Publicado: (2021)

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis
por: Dekker, Iris, et al.
Publicado: (2017)

Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
por: Hagens, Marloes HJ, et al.
Publicado: (2017)

The SRSF1 linker induces semi-conservative ESE binding by cooperating with the RRMs
por: Cho, Suhyung, et al.
Publicado: (2011)

Structural Brain Network Characteristics Can Differentiate CIS from Early RRMS
por: Muthuraman, Muthuraman, et al.
Publicado: (2016)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The MRI central vein marker; differentiating PPMS from RRMS and ischemic SVD
por: Samaraweera, Amal P.R., et al.
Publicado: (2018)

Distributed causality in resting-state network connectivity in the acute and remitting phases of RRMS
por: Wu, Lin, et al.
Publicado: (2020)

Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients
por: Balasa, Rodica, et al.
Publicado: (2022)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Evidence for cooperative tandem binding of hnRNP C RRMs in mRNA processing
por: Cieniková, Zuzana, et al.
Publicado: (2015)

EDSS and infratentorial white matter lesion volume are considered predictors of fatigue severity in RRMS
por: Ezzeldin, Mohammed Y., et al.
Publicado: (2023)

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?
por: Dekker, Iris, et al.
Publicado: (2019)

Vitamin D Status Is Positively Correlated with Regulatory T Cell Function in Patients with Multiple Sclerosis
por: Smolders, Joost, et al.
Publicado: (2009)

Safety and T Cell Modulating Effects of High Dose Vitamin D(3) Supplementation in Multiple Sclerosis
por: Smolders, Joost, et al.
Publicado: (2010)

Stress-Axis Regulation by Vitamin D(3) in Multiple Sclerosis
por: Rolf, Linda, et al.
Publicado: (2018)

Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis
por: Mimpen, Max, et al.
Publicado: (2021)

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
por: Freedman, Mark S., et al.
Publicado: (2014)

Prognostic value of natural killer cell/T cell ratios for disease activity in multiple sclerosis
por: Mimpen, Max, et al.
Publicado: (2020)

Structural insights into the targeting of mRNA GU-rich elements by the three RRMs of CELF1
por: Edwards, John M., et al.
Publicado: (2013)

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
por: Braune, Stefan, et al.
Publicado: (2013)

Lost in Classification: Lower Cognitive Functioning in Apparently Cognitive Normal Newly Diagnosed RRMS Patients
por: Pitteri, Marco, et al.
Publicado: (2019)

Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study
por: Dobreanu, Minodora, et al.
Publicado: (2021)

Three-year follow-up of serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in nursing home residents who had received 12 months of daily bread fortification with 125 μg of vitamin D(3)
por: Mocanu, Veronica, et al.
Publicado: (2013)

Emerging safety issues in alemtuzumab-treated MS patients
por: Killestein, Joep, et al.
Publicado: (2019)

A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study
por: Mattioli, Flavia, et al.
Publicado: (2015)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dveor2178843j2q80k24jpda7i